에 대한 최신 뉴스 U.S. Gold (NASDAQ:USAU) 주식

U.S. Gold

U.S. Gold Corp is an exploration and development company that owns certain mining leases and other mineral rights comprising the CK Gold Project in Wyoming, the Keystone Project in Nevada, and the Challis Gold Project in Idaho.

Commodities

USAU

2024년 5월 8일 주요뉴스 1. U.S. 골드(NYSE:USAU)은 자회사인 골드킹(Gold King)이 와이오밍주 환경부로부터 표면 금광 채굴 허가를 받아 프로젝트 개발에 한발 더 다가섰다고 발표했다. 조지 비(George Bee) 사장은 주요 규제 장애물의 해소와 최종 개발 승인 획득을 위한 진행 중인 상황을 강조했다.

수요일 주요 광업 뉴스: U.S. 골드, 아이반호 일렉트릭, 컴퍼스 미네랄스, 아이다호 스트래티직

Earnings

News

Small Cap

GORO

IONR

KALU

2024년 4월 16일의 핫한 뉴스: 1. 골드 리소스(NYSE:GORO)가 금 3,557온스과 은 21만 6,535온스의 판매를 포함한 2024년 1분기의 예비 결과를 발표했다. 이는 총 5,965온스의 금 상당량을 의미한다. 이번 분기에 회사는 또한 아연 1,682톤, 구리 264톤, 납 667톤을 판매했다. 

화요일 주요 광업 뉴스: 골드 리소스, 워딩턴 스틸, U.S. 골드, 아이오니어, 카이저

U.S. Gold Corp

Diamondback has entered into a definitive purchase agreement with Viper Energy, a subsidiary of Diamondback, to sell certain mineral and royalty interests from subsidiaries of Diamondback for $1 billion in cash and approximately&nbsp;69.6 million units of Viper's operating subsidiary in a drop down transaction.&nbsp;
The tax advantaged OpCo units, which will be issued together with an equal number of shares of Class B common stock of Viper, are exchangeable for shares of Class A common stock of Viper.
Based on the volume weighted average sales price of Viper's common stock for the 30-trading day period ending on January 24, 2025 of $49.55, the transaction is valued at a total of $4.45 billion. Viper expects to fund the cash portion of this transaction through a combination of cash on hand, borrowings under Viper's credit facility, and proceeds from one or more capital markets transactions, subject to market conditions and other factors.
 &nbsp;

FANG

VNOM

Diamondback Energy Reveals Drop Down Transaction With Viper Energy

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.hancockwhitney.com%2F&amp;esheet=54196820&amp;newsitemid=20250130463851&amp;lan=en-US&amp;anchor=Hancock+Whitney+Corporation&amp;index=1&amp;md5=3e785d5b69d75b5df7ea4d2ca2ed332f">Hancock Whitney Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWC#NASDAQ">HWC</a>) today announced that at its January meeting, the Company's Board of Directors ("the Board") approved a regular first quarter 2025 common stock cash dividend of $0.45 per common share, an increase of $0.05 per common share, or 12.5%. The first quarter dividend is payable on March 17, 2025 to shareholders of record as of March 5, 2025.

Dividends

Hancock Whitney Increases Quarterly Dividend From $0.40 To $0.45 Per Share

Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) reported quarterly earnings of $0.61 per share which beat the analyst consensus estimate of $0.38 by 60.53 percent. This is a 335.71 percent increase over earnings of $0.14 per share from the same period last year. The company reported quarterly sales of $16.79 million which beat the analyst consensus estimate of $13.80 million by 21.69 percent. This is a 33.40 percent increase over sales of $12.59 million the same period last year.

Earnings Beats

PDEX

Pro-Dex Q2 EPS $0.61 Beats $0.38 Estimate, Sales $16.79M Beat $13.80M Estimate

Guidance

INTC

Intel Sees Q1 2025 Revenue $11.7B-$12.7B vs $12.87B Est., Non-GAAP EPS $0.00 vs $0.09 Est.

Intel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) reported quarterly earnings of $0.13 per share which beat the analyst consensus estimate of $0.12 by 8.33 percent. This is a 75.93 percent decrease over earnings of $0.54 per share from the same period last year. The company reported quarterly sales of $14.300 billion which beat the analyst consensus estimate of $13.810 billion by 3.55 percent. This is a 7.18 percent decrease over sales of $15.406 billion the same period last year.

Intel Q4 2024 Adj. EPS $0.13 Beats $0.12 Estimate, Sales $14.300B Beat $13.810B Estimate

Automatic Data Processing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADP#NASDAQ">ADP</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $313.75, a high estimate of $325.00, and a low estimate of $305.00. This current average reflects an increase of 4.93% from the previous average price target of $299.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1738270876_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Automatic Data Processing. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$315.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Samad Samana</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$305.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Dan Dolev</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$310.00</td>
<td>$281.00</td>
</tr>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$325.00</td>
<td>$310.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Automatic Data Processing. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Automatic Data Processing compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Automatic Data Processing's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Automatic Data Processing's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ADP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Automatic Data Processing analyst ratings.</a>
<h2>Delving into Automatic Data Processing's Background</h2>
ADP is a provider of payroll and human capital management solutions servicing the full scope of businesses from micro to global enterprises. ADP was established in 1949 and serves over 1 million clients primarily in the United States. ADP's employer services segment offers payroll, human capital management solutions, human resources outsourcing, insurance and retirement services. The smaller but faster-growing professional employer organization segment provides HR outsourcing solutions to small and midsize businesses through a co-employment model.
<h3>Automatic Data Processing: Financial Performance Dissected</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Automatic Data Processing's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 6.23%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Industrials sector.
Net Margin: Automatic Data Processing's net margin is impressive, surpassing industry averages. With a net margin of 20.88%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Automatic Data Processing's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 19.33%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Automatic Data Processing's ROA stands out, surpassing industry averages. With an impressive ROA of 1.84%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Automatic Data Processing's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.75, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

4 Analysts Have This To Say About Automatic Data Processing

In the latest quarter, 6 analysts provided ratings for SEI Inv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEIC#NASDAQ">SEIC</a>), showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated SEI Inv and provided 12-month price targets. The average target is $89.33, accompanied by a high estimate of $99.00 and a low estimate of $80.00. This upward trend is apparent, with the current average reflecting a 11.94% increase from the previous average price target of $79.80.
<img src="https://www.benzinga.com/files/images/story/2025/1738270868_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of SEI Inv by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aidan Hall</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$90.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Patrick O'Shaughnessy</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$99.00</td>
<td>-</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$94.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Rayna Kumar</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$80.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Crispin Love</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$87.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Aidan Hall</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$86.00</td>
<td>$76.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to SEI Inv. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of SEI Inv compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of SEI Inv's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of SEI Inv's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SEIC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on SEI Inv analyst ratings.</a>
<h2>About SEI Inv</h2>
SEI Investments provides investment processing, management, and operations services to financial institutions, asset managers, asset owners, and financial advisors in four material segments: private banks, investment advisors, institutional investors, and investment managers. SEI also has a minority interest in LSV Asset Management, a value equity asset manager with about $99 billion in assets under management. As of December 2023, SEI (including LSV) manages, administers, or advises about $1.4 trillion in assets.
<h3>SEI Inv: Delving into Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: SEI Inv displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 12.72%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: SEI Inv's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 28.82%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): SEI Inv's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 6.73%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): SEI Inv's ROA stands out, surpassing industry averages. With an impressive ROA of 5.94%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: SEI Inv's debt-to-equity ratio is below the industry average. With a ratio of 0.01, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SEIC

Assessing SEI Inv: Insights From 6 Financial Analysts

Analysts' ratings for Packaging Corp of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKG#NYSE">PKG</a>) over the last quarter vary from bullish to bearish, as provided by 5 analysts.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $259.6, along with a high estimate of $282.00 and a low estimate of $235.00. This current average has increased by 5.19% from the previous average price target of $246.80. 
<img src="https://www.benzinga.com/files/images/story/2025/1738270857_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of Packaging Corp of America by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Roxland</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$265.00</td>
<td>$282.00</td>
</tr>
<tr>
<td>Gabe Hajde</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$236.00</td>
<td>$253.00</td>
</tr>
<tr>
<td>Anthony Pettinari</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$235.00</td>
<td>$232.00</td>
</tr>
<tr>
<td>Michael Roxland</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$282.00</td>
<td>$252.00</td>
</tr>
<tr>
<td>Philip Ng</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$280.00</td>
<td>$215.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Packaging Corp of America. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Packaging Corp of America compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Packaging Corp of America's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Packaging Corp of America's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/PKG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Packaging Corp of America analyst ratings.</a>
<h2>Get to Know Packaging Corp of America Better</h2>
Packaging Corp. of America is the third-largest containerboard and corrugated packaging manufacturer in the United States. It produces over 4.5 million tons of containerboard annually. The company's share of the domestic containerboard market is roughly 10%. PCA differentiates itself from larger competitors by focusing on smaller customers and operating with a high degree of flexibility.
<h3>Financial Insights: Packaging Corp of America</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Packaging Corp of America's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 12.73%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Materials sector.
Net Margin: Packaging Corp of America's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 10.83%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Packaging Corp of America's ROE excels beyond industry benchmarks, reaching 5.64%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Packaging Corp of America's ROA stands out, surpassing industry averages. With an impressive ROA of 2.67%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.65.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Packaging Corp of America Stock: Analyst Perspectives (5 Ratings)

Throughout the last three months, 5 analysts have evaluated Renasant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNST#NYSE">RNST</a>), offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Renasant, revealing an average target of $45.2, a high estimate of $47.00, and a low estimate of $44.00. Marking an increase of 5.12%, the current average surpasses the previous average price target of $43.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1738270838_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Renasant among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matt Olney</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$47.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Catherine Mealor</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$46.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Michael Rose</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$44.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Stephen Scouten</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$44.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Catherine Mealor</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Renasant. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Renasant compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Renasant's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Renasant's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RNST/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Renasant analyst ratings.</a>
<h2>Get to Know Renasant Better</h2>
Renasant Corp operates as a holding company for Renasant Bank, a Mississippi banking corporation, and its subsidiary, Renasant Insurance, Inc. It has three reportable segments: community banks, insurance, and wealth management. With its community banks segment, the company provides a range of financial services to individuals and small businesses. Its insurance segment is an insurance agency providing commercial and personal insurance through third-party carriers. The wealth management segment provides a range of services including money management and retirement planning. The majority of the company's revenue is driven by lending activities in its community banks segment. Renasant Corporation operates in the southern United States.
<h3>Key Indicators: Renasant's Financial Health</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Renasant's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 0.09%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: Renasant's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 26.78% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Renasant's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 1.68%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Renasant's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.25%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.2.
<h2>What Are Analyst Ratings?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RNST

What Analysts Are Saying About Renasant Stock

In the last three months, 6 analysts have published ratings on Five Star (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSBC#NASDAQ">FSBC</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $36.42, a high estimate of $38.50, and a low estimate of $35.00. Observing a downward trend, the current average is 0.9% lower than the prior average price target of $36.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1738270828_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Five Star among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gary Tenner</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$38.50</td>
<td>$38.50</td>
</tr>
<tr>
<td>Andrew Terrell</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$36.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Wood Lay</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$35.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>David Feaster</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$35.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Andrew Terrell</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$37.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Wood Lay</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$37.00</td>
<td>$33.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Five Star. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Five Star compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Five Star's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/FSBC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Five Star analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Five Star</h2>
Five Star Bancorp is a California state-chartered non-member bank. The Company provides a broad range of banking products and services to small and medium-sized businesses, professionals, and individuals. It offers loan products like commercial real estate loans, commercial loans, commercial land and construction loans, and farmland loans and offers deposit products like checking accounts, savings accounts, money market accounts, and term certificate accounts.
<h3>Five Star: Delving into Financials</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Five Star's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 10.38%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Five Star's net margin is impressive, surpassing industry averages. With a net margin of 34.76%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Five Star's ROE excels beyond industry benchmarks, reaching 2.84%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Five Star's ROA excels beyond industry benchmarks, reaching 0.29%. This signifies efficient management of assets and strong financial health.
Debt Management: Five Star's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.21.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FSBC

Expert Outlook: Five Star Through The Eyes Of 6 Analysts

In the preceding three months, 4 analysts have released ratings for Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>), presenting a wide array of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Spero Therapeutics and provided 12-month price targets. The average target is $5.0, accompanied by a high estimate of $5.00 and a low estimate of $5.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 9.09%. 
<img src="https://www.benzinga.com/files/images/story/2025/1738270812_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of Spero Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Josh Schimmer</td>
<td>Evercore ISI Group</td>
<td>Maintains</td>
<td>In-Line</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$5.00</td>
<td>$7.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Spero Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Spero Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Spero Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Spero Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SPRO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Spero Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Spero Therapeutics</h2>
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
<h3>A Deep Dive into Spero Therapeutics's Financials</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Decline in Revenue: Over the 3 months period, Spero Therapeutics faced challenges, resulting in a decline of approximately -66.56% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Spero Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of -219.3%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Spero Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of -23.49%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Spero Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -12.03%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Spero Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.07.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SPRO

The Analyst Verdict: Spero Therapeutics In The Eyes Of 4 Experts

WIIM

USDMXN

USD/MXN is higher after US President Trump reportedly said he will put a 25% tariff on Canada and Mexico.

<a href="https://register.epo.org/application?number=EP19847261">https://register.epo.org/application?number=EP19847261</a>
&nbsp;
<figure class="image"><img src="https://pbs.twimg.com/media/Gikb5A4bYAAPTeO?format=jpg&amp;name=small" alt="Image" /></figure>

TRNR

Interactive Strength Has Received A Decision To Grant European Patent Number EP3833455 Titled "INTERACTIVE EXERCISE MACHINE DATA ARCHITECTURE (INCLUDING A CLOUD PROCESSING SYSTEM)".

LCFY

Locafy shares are trading higher after the company announced a strategic partnership with Fathom Holdings to boost SEO.

Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)&nbsp;<a target="_blank" href="https://www.benzinga.com/topic/amazon" rel="noreferrer noopener">downsized dozens of people</a> in its communications and sustainability units after a recent review to cut costs, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-01-29/amazon-cuts-dozens-of-corporate-jobs-in-latest-round-of-layoffs?srnd=phx-technology&amp;sref=TBDibEcD" rel="noreferrer noopener">reports</a>.
The e-commerce giant might rehire some employees for roles at lower levels and redistribute the headcount to other areas within the organization, CNBC <a target="_blank" href="https://www.cnbc.com/2025/01/29/amazon-cuts-some-jobs-in-its-communications-sustainability-units.html" rel="noreferrer noopener">reports</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/01/43345282/mastercard-q4-earnings-revenue-and-eps-beat-strong-growth-in-payments-and-cross-border-transactions" rel="noreferrer noopener">Mastercard Q4 Earnings: Revenue And EPS Beat, Strong Growth In Payments and Cross-Border Transactions</a>
The reports said Amazon will provide financial support and benefits to the affected workers.
Amazon&#8217;s global workforce surged to over 1.6 million by 2021 during the COVID-19 pandemic, up from 798,000 in the fourth quarter of 2019. The company had more than 1.5 million employees&nbsp;at the end of the third quarter.
Recently, the company withdrew its operations in Quebec, Canada, and slashed close to <a target="_blank" href="https://www.benzinga.com/25/01/43155691/amazon-shuts-quebec-operations-1700-jobs-lost-tariff-threat-looms" rel="noreferrer noopener">1,700 full-time jobs</a>.
Amazon initiated a record corporate downsizing&nbsp;in 2022, affecting 27,000 positions, followed by multiple smaller rounds of layoffs. The company also urged its employees to report to the office five days a week.
A similar trend is seen with other tech companies. <a target="_blank" href="https://www.benzinga.com/media/25/01/43003727/microsoft-to-cut-costs-pause-hiring-in-us-consulting-tighten-spending" rel="noreferrer noopener">Recent reports indicated</a> that Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) plans to halt hiring in part of its U.S. consulting business, affecting less than 1% of its workforce.
Microsoft fired 10,000 employees in early 2023, implying 4%-5% of its workforce. In January 2024, Microsoft&#8217;s gaming unit slashed 1,900 jobs.
In 2023, Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google&nbsp;cut 12,000 jobs, affecting ~6% of its workforce. Since November 2022, Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) said it had laid off 21,000 employees, implying 25% of its workforce.&nbsp;
Analysts from Needham and BofA Securities have <a target="_blank" href="https://www.benzinga.com/analyst-ratings/price-target/25/01/43110753/aws-robotics-prime-video-ads-fuel-amazon-growth-potential-analysts" rel="noreferrer noopener">expressed optimism on</a> Amazon&#8217;s prospects, citing Amazon Web Services growth, retail margin efficiency, and substantial AI-driven cloud opportunities. Amazon&#8217;s focus on robotics, Prime Video ads, and cloud innovation positioned the company for multi-year profit growth.
Amazon stock gained 48% in the last 12 months. Investors can gain exposure to Amazon through Fidelity MSCI Consumer Discretionary Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDIS#NYSE">FDIS</a>) and ProShares Online Retail ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONLN#NYSE">ONLN</a>).
Price Action: AMZN stock is down 0.63% at $235.52 at last check Thursday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/25/01/43322963/nvidia-positioned-for-400-billion-ai-boom-with-advanced-gpus-new-product-launches-driving-revenue-gr" target="_blank" rel="noreferrer noopener">Nvidia Positioned For $400 Billion AI Boom With Advanced GPUs, New Product Launches Driving Revenue Growth, Say Analysts</a></li>
</ul>
Image via Shutterstock

Tech

Media

AMZN

FDIS

GOOG

GOOGL

MSFT

ONLN

Amazon Cuts More Jobs in Cost-Saving Push: Report

USDCAD

USD/CAD is higher after US President Trump reportedly said he will put a 25% tariff on Canada and Mexico.

Macro Economic Events

Economics

President Trump Says Will Decide Probably Thursday Night Whether To Impose Tariffs On Oil On Canada And Mexico; Oil Price Is A Factor In Tariff Determination

A single oral dose of SYMBRAVO provided rapid migraine pain freedom and return to normal functioning within 2 hours, and sustained efficacy through 24 and 48 hours
85% and 77% of patients treated with a single dose of SYMBRAVO did not require migraine rescue medication within 24 hours in two Phase 3 studies
SYMBRAVO demonstrated superior efficacy across a broad range of migraine severity (mild, moderate, and severe), and in head-to-head evaluation
SYMBRAVO incorporates Axsome's rapid absorption technology and mechanisms that target multiple migraine attack pathways
Company to host conference call and webcast Friday, January 31, at 8:00 AM Eastern
NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has approved SYMBRAVO&#xAE; (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults.1 SYMBRAVO represents a novel multi-mechanistic approach to treating migraine that targets multiple pathways underlying a migraine attack. SYMBRAVO can rapidly eliminate migraine pain and return patients to normal functioning, with efficacy sustained through 24 and 48 hours in some patients after a single dose. The efficacy of SYMBRAVO was demonstrated across a broad range of settings including at the earliest onset of migraine when the pain was mild, in patients with moderate and severe migraine pain, and in those with a history of various responses to prior acute treatments. The Company expects SYMBRAVO to be commercially available in the U.S. in approximately four months.

Biotech

General

AXSM

Axsome Therapeutics Announces FDA Approval Of SYMBRAVO For The Acute Treatment Of Migraine With Or Without Aura In Adults; 85% And 77% Of Patients Treated With A Single Dose Of SYMBRAVO Did Not Require Migraine Rescue Medication Within 24 Hours In Two Phase 3 Studies

Shares of US auto stocks are trading higher after US President Trump reportedly said he will put a 25% tariff on Canada and Mexico.

Columbia Banking System's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COLB#NYSE">COLB</a>) short percent of float has risen 11.26% since its last report. The company recently reported that it has 4.61 million shares sold short, which is 2.47% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.44 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Columbia Banking System Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738269923_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Columbia Banking System has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Columbia Banking System's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Columbia Banking System's peer group average for short interest as a percentage of float is 4.01%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

COLB

Peering Into Columbia Banking System's Recent Short Interest

H.C. Wainwright analyst Heiko Ihle reiterated a Buy rating on US Gold (USAU – Research Report) today and set a price target of $11.00. Heiko Ihle h...

Optimization and Strategic Location Bolster Buy Rating for US Gold Corp's CK Gold Project

Commodity Roundup: Gold notches record high on large rate cut bets, oil eyes weekly gain

Catalyst Watch: FOMC, FedEx earnings, Electronic Arts event, and triple witching day

Top quant-rated Commodity miners as gold hits record highs

Biden pushes ahead with methane fee despite Trump's win, asks E.U. to align with U.S.

U.S. Gold wins final permit for Wyoming mining project, starting PFS work

H.C. Wainwright analyst Heiko Ihle raised the firm's price target on U.S. Gold (USAU) to $13 from $11 and keeps a Buy rating on the shares after th...

U.S. Gold price target raised to $13 from $11 at H.C. Wainwright

U.S. Gold secures $10.2M financing

US Gold ( ($USAU) ) just unveiled an update. U.S. Gold Corp. has announced a registered direct offering of common stock and warrants, estimated to ...

US Gold Announces Stock Offering to Raise $10.2M

Roth MKM initiated coverage of U.S. Gold (USAU) with a Buy rating and $10 price target The stock is undervalued by the market for its CK Gold Proje...

U.S. Gold initiated with a Buy at Roth MKM

AAAU

ALAB

ALTM

AMPS

AMTX

ARREF

ASTS

AUIAF

BCDA

BIRK

BLDP

BOIL

BYDDF

CART

CMCL

CRML

CRWD

CSCO

CYBN

DECK

DRIP

ELTP

EXPD

FCEL

FERG

FFIE

FSLR

GATO

GDXJ

GLDM

GOTRF

GUSH

HNRG

HUBS

HYMC

INDO

IVPAF

KOLD

LICY

LSTR

LTBR

LYSDY

NPWR

NUGT

NVDA

OKLO

OMEX

OUNZ

PETQ

PHYS

PLCE

PLUG

PPTA

PSLV

QCOM

RBLX

RDDT

SBSW

SEDG

SGOL

SHAK

SILJ

SILV

SIVR

SMTSF

STLA

TECK

TMUS

TPIC

TSLA

USOI

VOXR

VTLE

VZLA

WDAY

ZVRA

Press Releases

U.S. Gold Corp. to Participate at the Gold Forum Americas 2024 Conference in Colorado Springs, Colorado

U.S. Gold Corp's Fall Conference Takeaway Spotlights Developers with Permitted, Derisked Projects in Mining-Friendly Jurisdictions

Winning Media Announces Exclusive Interview With US Gold Corp Chairman and Co-Founder, Luke Norman

U.S. Gold Corp. Chairman to Appear on Live Gold Panel "Mined in the USA"

U.S. Gold Corp. Receives Air Quality Permit, Finalizing the Mine Operating Permit for the CK Gold Project

U.S. Gold Corp. to Participate in New Orleans Investment Conference and CEM Florida Capital Event November 20-24

Offerings

U.S. GOLD CORP. ANNOUNCES $10.2 MILLION REGISTERED DIRECT OFFERING

U.S. Gold Corp. Closes $10.2 Million Non-Brokered Registered Direct Offering

U.S. Gold Corp. Provides Commentary on $10.2 Million Non-Brokered Registered Direct Offering and CK Gold Project Update

U.S. Gold Corp. to Participate at the 2025 Future Minerals Forum in Riyadh, Saudi Arabia

American Battery Technology Company - Common Stock

American Battery Tech

BHP Group Limited American Depositary Shares (Each representing two Ordinary Shares)

Comments

U.S. Gold

뉴스

에 대한 최신 뉴스 U.S. Gold (NASDAQ:USAU) 주식

수요일, 5월 08, 2024

화요일, 4월 16, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌